Foghorn Therapeutics Profit Margin

Foghorn Therapeutics (FHTX) currently reports a profit margin of -2.67% as of March 2026. That compares with -3.42% in the prior-year period — up 22.0% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Foghorn Therapeutics's profit margin history and peer comparisons.

Foghorn Therapeutics's profit margin increased from -3.42% to -2.67% — a 22.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Foghorn Therapeutics's profit margin of -2.67% is lower than the Healthcare sector average of 15.58%. That is roughly 1812.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Foghorn Therapeutics's current -2.67% should be judged against Healthcare norms (sector average: 15.58%) and against FHTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Foghorn Therapeutics, and consider following FHTX for alerts when major investors trade the stock.